High Prescription Rate of Medications With Rifampin Drug–drug Interactions in Patients With Diabetic Foot Osteomyelitis: Should Rifabutin Be Included in Clinical Trials for Adjunctive Therapy?

• Type of Material: Article
• Authors: Christina Mallarino-Haeger, Emory University; Allison Watson, Emory University; Umnia Mahgoub, Emory University; Lily Francis, Augusta University; Maryam Heydari, Emory University; Muaaz Choudhary, Temple University; Manuel Garcia-Toca, Emory University; Manish Patel, Emory University; Russell R. Kempker, Emory University; Maya Fayfman, Grady Health System; Marcos C. Schechter, Emory University
• Language: English
• Date: 2024-10-11
• Publisher: Oxford University Press
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): https://doi.org/10.1093/ofid/ofae582
• Title of Journal or Parent Work: Open Forum Infectious Diseases
• Volume: 11
• Issue: 11
• Start Page: ofae582
• Keywords: rifamycins; drug-drug interactions; diabetic foot osteomyelitis

Abstract

Rifampin may improve diabetic foot osteomyelitis outcomes, but its extensive drug–drug interactions could hamper its use. Here, through a review of the medications prescribed to a cohort of 190 persons with diabetic foot osteomyelitis, we show that rifabutin, a rifamycin with fewer drug–drug interactions, would be easier to implement in practice.